Paxlovid in Pregnancy
Pregnant patients with non-severe COVID-19 at high risk for hospitalization may consider using Paxlovid (nirmatrelvir-ritonavir), as WHO guidelines explicitly support this option to reduce disease progression, with no reports of serious adverse reactions in mothers or infants to date.
Evidence-Based Recommendation
The WHO Living Guideline (updated November 2023) provides the clearest guidance: nirmatrelvir/ritonavir represents an option for pregnant people with COVID-19 to reduce the risk of disease progression 1. This recommendation is particularly important because:
- High certainty evidence shows important reduction in hospitalization risk
- Moderate certainty evidence demonstrates survival benefit
- No increase in adverse events compared to placebo
- WHO Vigibase surveillance shows no reports of serious adverse reactions in pregnant or breastfeeding people or their children despite acknowledged uncertainty 1
Clinical Application Algorithm
Step 1: Assess Eligibility
- Disease severity: Non-severe COVID-19 (not requiring hospitalization)
- Risk stratification: High risk for progression (age >35, comorbidities like hypertension, diabetes, obesity, chronic lung/heart/kidney disease)
- Timing: Within 5 days of symptom onset
- Gestational age: Any trimester (most data from third trimester patients)
Step 2: Screen for Contraindications
- Drug interactions: Ritonavir is a potent CYP3A inhibitor—review ALL medications using Liverpool COVID-19 drug interaction tool 1, 2
- Renal function: Check eGFR (dose reduce if 30-59 mL/min; avoid if <30 mL/min) 2
- Hepatic function: Avoid in severe hepatic impairment (Child-Pugh Class C) 2
- Hypersensitivity: History of reactions to nirmatrelvir or ritonavir 2
Step 3: Dosing
- Standard dose: Nirmatrelvir 300 mg (two 150 mg tablets) + ritonavir 100 mg, taken together twice daily for 5 days 1, 2
- Moderate renal impairment (eGFR 30-59): Reduce to nirmatrelvir 150 mg + ritonavir 100 mg twice daily 1, 2
Supporting Research Evidence
Recent systematic review and meta-analysis (2025) of 427 pregnant patients treated with nirmatrelvir-ritonavir showed 3:
- Hospitalization rate: Only 2% (95% CI: 1%-5%)
- Drug discontinuation: 0.7% due to adverse effects
- No maternal or neonatal deaths reported
- Mean birth weight: 3186 g (normal range)
A Johns Hopkins case series (2022) of 47 pregnant patients demonstrated 4:
- Good tolerability: Only 2 patients (4.3%) discontinued due to adverse effects
- Low hospitalization: 2 patients (4.3%) hospitalized for pre-existing comorbidities, not COVID-19
- Treatment timing: Median 1 day after symptom onset
- Completion rate: 95.7% completed full 5-day course
Critical Caveats and Pitfalls
Drug-Drug Interactions
This is the primary concern. Ritonavir causes significant drug interactions that persist for several days after treatment completion 1, 2. Common problematic medications in pregnancy include:
- Certain antihypertensives
- Anticonvulsants
- Immunosuppressants
- Statins
- Some psychiatric medications
Action: Use the Liverpool COVID-19 drug interaction checker BEFORE prescribing 1.
HIV Considerations
Paxlovid may lead to HIV-1 protease inhibitor resistance in undiagnosed HIV infection 2. Consider HIV testing if status unknown, particularly in high-prevalence populations.
Limited Pregnancy-Specific Data
While WHO acknowledges uncertainty regarding potential serious adverse reactions, the absence of reported harm in WHO Vigibase surveillance is reassuring 1. The FDA label does not specifically contraindicate use in pregnancy but notes limited data 2.
Comparison to Alternatives
- Remdesivir: Requires IV administration (feasibility concerns), similar efficacy 1
- Molnupiravir: Concerns about possible harms, less preferred 1
- Monoclonal antibodies: No longer recommended due to variant resistance 5
Divergent Evidence Considerations
The 2023 scoping review noted variable international guidance 5:
- UK and Australia: Initially authorized only in research settings; UK withdrew recommendation by end of 2022
- WHO: Supports use with informed decision-making
- Most recent evidence (2025-2026): Increasingly supportive of safety and efficacy 3, 6, 7
This divergence reflects the evolving evidence base. The most recent systematic review (2025) and WHO guideline update (2023) provide the strongest support for use 1, 3.
Risk-Benefit Framework
Benefits clearly outweigh risks when:
- Patient has high-risk features for severe COVID-19
- No significant drug interactions present
- Treatment can be initiated within 5 days of symptoms
- Patient understands limited pregnancy-specific data but reassuring safety signals
The key clinical decision is whether drug interactions can be safely managed—if yes, proceed with treatment given the proven mortality and hospitalization benefits 1.